Thinking of joining a study?

Register your interest

Become a volunteer?

NCT06158802 | RECRUITING | Human Papillomavirus Vaccine

Evaluation of Human Papillomavirus Vaccine Coverage in Girls and Young Women with Chronic Disease
Sponsor:

Public assistance - Paris hospitals

Brief Summary:

The main objective of the study is to determine the vaccination coverage rate for human papillomavirus in adolescents aged 11 to 20 with chronic disease and treated at the Necker-Enfants Malades Hospital, compared to a population witnessed adolescent girls aged 11 to 20 years without chronic disease.

Condition or disease

Human Papillomavirus Vaccine

Chronic Condition

Intervention/treatment

Questionnaire

Detailed Description:

Girls and young women with chronic condition are at higher risk for infections that can be prevented by vaccination. Human papillomavirus infection is very common, one of the three most common in the general population. A vaccine exists to significantly prevent this infection and its complications. In France, it is advisable to vaccinate girls and boys from the age of 9 years and as soon as possible in the case of acquired immunodeficiency since these patients are more likely to be suffering from cancer induced by the human papillomavirus. In France, the overall rate of vaccination coverage for girls is 21%, which is significantly lower than in several other industrialized countries. The vaccination coverage rate for human papillomavirus in patients with chronic diseases may be even lower. The main objective of the study is to determine the vaccination coverage rate for human papillomavirus in adolescents aged 11 to 20 with chronic condition and treated at the Necker-Enfants Malades Hospital, compared to a population witnessed adolescent girls aged 11 to 20 years without chronic disease.

Study Type : OBSERVATIONAL
Estimated Enrollment : 448 participants
Official Title : Evaluation of Human Papillomavirus Vaccine Coverage in Girls and Young Women with Chronic Disease
Actual Study Start Date : 2024-01-23
Estimated Primary Completion Date : 2025-07
Estimated Study Completion Date : 2025-07

Information not available for Arms and Intervention/treatment

Ages Eligible for Study: 11 Years to 20 Years
Sexes Eligible for Study: FEMALE
Accepts Healthy Volunteers:
Criteria
Inclusion Criteria
  • * Information and non-opposition of major patients and holders of parental authority of minor patients and minor patients
  • * Girls and young women aged 11 to 20
  • * To be followed at the Necker-Enfants Malades Hospital ("chronic condition" group)
  • * To be followed at the Specialized Medical Center for Children and Adolescents ("control" group)
  • * Have a chronic condition ("chronic condition" group)
    • * Diabetes type 1
    • * Metabolic diseases
    • * Patients followed in immuno-hematology
    • * Cystic Fibrosis
    • * Sickle
    • * Kidney transplant
    • * Heart Disease
    • * Inflammatory bowel diseases
    • * Rare anorectal and pelvic anomalies
    • * Live in France
    • * Comprehension of the French language (oral and written)
    Exclusion Criteria
    • * Have a contraindication to the HPV vaccine - Gardasil 9 (Vidal Hoptimal, 2018)
    • * Have a contraindication to the HPV vaccine - Gardasil (Vidal Hopitmal, 2018)
    • * Have a contraindication to HPV vaccine - Cervarix (Vidal Hoptimal, 2018)
Evaluation of Human Papillomavirus Vaccine Coverage in Girls and Young Women with Chronic Disease

Location Details

NCT06158802

Please Choose a site

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations

RECRUITING

France,

Child and adolescent specialized medical center (CMSEA)

Paris, France, 75011

RECRUITING

France,

Necker-Enfants Hospital

Paris, France, 75015